Losartan Protects Podocytes against High Glucose-induced Injury by Inhibiting B7-1 Expression

Abstract

The role of B7-1 in podocyte injury has received increasing attention. The aim of this study was to investigate whether losartan protects podocytes of patients with diabetic kidney disease (DKD) by regulating B7-1 and the underlying mechanisms. Rats with streptozotocin-induced DKD were treated with losartan for 8 weeks. Biochemical changes in blood and urine were analyzed. Kidneys were isolated for electron microscopy, immunofluorescence, real-time quantitative PCR (RT-PCR), and Western blot analysis. Immortalized mouse podocyte cells were cultured in normal or high glucose medium in the presence or absence of losartan for 48 h, and then the cells were collected for immunofluorescence, PCR, Western blotting and monolayer permeability detection. The phosphatidylinositol 3-kinase (PI3K) 110α subunit and angiotensin II type 1 receptor (AT1R) plasmids were transfected into podocytes, respectively, and then Western blotting was performed to assess the expression of B7-1 protein. The results showed that losartan ameliorated podocyte structure and function in the rat model of DKD, and reduced the expression of B7-1 protein. Overexpression of PI3K 110α subunit in podocytes attenuated the inhibitory effect of losartan on B7-1 expression in high glucose-stimulated podocytes. The expression of B7-1 was significantly increased by overexpression of AT1R and significantly reduced by blocking PI3K 110α subunit. We conclude that losartan protects podocytes against high glucose-induced injury by inhibiting AT1R-mediated B7-1 expression. This effect is dependent on the AT1R-PI3K 110α subunit pathway.

Keywords

B7-1 / podocyte / losartan / diabetic kidney disease (DKD) / PI3K 110α subunit / angiotensin II / type 1 receptor (AT1R)

References

[1] ZhangL, LongJ, JiangW, et al.. Trends in chronic kidney disease in china. N Engl J Med, 2016, 375(9): 905-906

[2] BassiR, FornoniA, DoriaA, et al.. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease. Diabetologia, 2016, 59(1): 21-29

[3] PichaiwongW, HudkinsKL, WietechaT, et al.. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. J Am Soc Nephrol, 2013, 24(7): 1088-1102

[4] SunX, FangZ, ZhuZ, et al.. Effect of down-regulation of TRPC6 on the puromycin aminonucleoside-induced apoptosis of mouse podocytes. J Huazhong Univ Sci Technolog Med Sci, 2009, 29(4): 417-422

[5] SunX, ChuY, ZhangC, et al.. Effect of TRPC6 knockdown on puromycin Aminonucleoside-induced podocyte injury. J Huazhong Univ Sci Technolog Med Sci, 2012, 32(3): 340-345

[6] FengY, HuangR, KavanaghJ, et al.. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis. Am J Cardiovasc Drugs, 2019, 19(3): 259-286

[7] CaiJ, HuangX, ZhengZ, et al.. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis. Nephrol Dial Transplant, 2018, 33(11): 1968-1976

[8] MuC, ZhangX, WangL, et al.. Enhanced suppression of polyclonal CD8+ 25+ regulatory T cells via exosomal arming of antigen-specific peptide/MHC complexes. J Leukoc Biol, 2017, 101(5): 1221-1231

[9] CaiM, ZhouT, WangX, et al.. DC-SIGN expression on podocytes and its role in inflammatory immune response of lupus nephritis. Clin Exp Immunol, 2016, 183(3): 317-325

[10] NettiGS, SangregorioF, SpadaccinoF, et al.. LPS removal reduces CD80-mediated albuminuria in critically ill patients with Gram-negative sepsis. Am J Physiol Renal Physiol, 2019, 316(4): F723-F731

[11] KhullarB, BalyanR, OswalN, et al.. Interaction of CD80 with Neph1: a potential mechanism of podocyte injury. Clin Exp Nephrol, 2018, 22(3): 508-516

[12] ReiserJ, AlachkarN. Proteinuria: abate or applaud abatacept in proteinuric kidney disease?. Nat Rev Nephrol, 2014, 10(3): 128-130

[13] MallipattuSK, HeJC. The podocyte as a direct target for treatment of glomerular disease?. Am J Physiol Renal Physiol, 2016, 311(1): 46-51

[14] LiuY, ShiY, RenR, et al.. Advanced therapeutics in focal and segmental glomerulosclerosis. Nephrology (Carlton), 2018, 23(4): 57-61

[15] SalantDJ. Podocyte expression of B7-1/CD80: Is it a reliable biomarker for the treatment of proteinuric kidney diseases with Abatacept?. J Am Soc Nephrol, 2016, 27(4): 963-965

[16] GagliardiniE, NovelliR, CornaD, et al.. B7-1 Is not induced in podocytes of human and experimental diabetic nephropathy. J Am Soc Nephrol, 2016, 27(4): 999-1005

[17] NorlinJ, Nielsen FinkL, Helding KvistP, et al.. Abatacept treatment does not preserve renal function in the streptozocin-induced model of diabetic nephropathy. PLoS One, 2016, 11(4): 0152315

[18] FiorinaP, VerganiA, BassiR, et al.. Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol, 2014, 25(7): 1415-1429

[19] BassiR, FornoniA, DoriaA, et al.. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease. Diabetologia, 2016, 59(1): 21-29

[20] XuHZ, WangWN, ZhangYY, et al.. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli. J Nephrol, 2016, 29(6): 775-782

[21] LewkoB, MarynA, LatawiecE, et al.. Angiotensin II modulates podocyte glucose transport. Front Endocrinol (Lausanne), 2018, 24(9): 418

[22] ParkHY, SeongSB, MinSY, et al.. CD2-associated protein/phosphoinositide 3-kinase signaling has a preventive role in angiotensin II-induced podocyte apoptosis. Int J Biochem Cell Biol, 2016, 79(10): 370-381

[23] ChoiJY, HaTS, ParkHY, et al.. Angiotensin D suppresses adenosine monophosphate-activated protein kinase of podocytes via angiotensin II type 1 receptor and mitogen-activated protein kinase signaling. Clin Exp Nephrol, 2013, 17(1): 16-23